One intelligence layer. Every manufacturing context.

A CDMO runs the same bioreactor or fill-finish line for multiple clients, on multiple products, across multiple sites. The batch-loss pain is the same, but the economic pressure is amplified: a lost batch is a lost client relationship, not just a COGS event.

Praescia’s density model is built for this. One validated golden-trajectory model validated on a process type can be deployed across every line running that process — at every site. The marginal cost of adding a second line is near zero. The network benchmarking tier appears as line count grows, giving CDMO operations a fleet-level view no single-site customer can reach.

What the density model enables

• One validation, many lines. Validate the model once per process type; deploy across every line running it. The CSV burden is amortized, not multiplied.
• Cross-client process benchmarking. Anonymized performance patterns across clients (pattern-only, never raw data) surface what “good” looks like at fleet scale.
• Fleet-wide deviation triage. A systemic issue on a process type surfaces as a pattern before it appears as individual batch deviations.
• Margin-expanding unit economics. Each new line added under an existing validated model is high-margin expansion — the intelligence is already there.

Manufacturing Science and Technology (MSAT) and process development teams are closest to the batch. They own the golden-trajectory definition, the deviation investigation, and the tech transfer package. They are also the team most affected when a batch is lost — a single bioreactor batch for a high-value biologic or cell therapy is worth $100k–millions, and for a cell or gene therapy it is one patient’s only dose.

Praescia gives MSAT teams foreknowledge: the deviation detected while there is still time to intervene, the titer shortfall projected before the release assay, the tech transfer drift caught on the first transfer run rather than at the post-mortem.

MSAT use cases

• Golden-batch deviation detection. Continuous comparison of the live run against the golden trajectory; deviation onset surfaced with reason and recommended intervention.
• Pre-harvest titer / yield prediction. Outcome projected at hours-to-days pre-harvest, while process adjustment is still actionable.
• Tech transfer fidelity. New-site runs compared against the reference process in real time; drift surfaced at the first batch, not at tech transfer review.
• Scale-up state monitoring. Preserve the state/transition model across scale (bench → pilot → manufacturing); differences in state transitions are the diagnostic.

Cell and gene therapy manufacturing is the highest-stakes context in biopharma. A single patient-specific batch may be one dose of therapy for one patient, with no ability to retry if the batch fails. The batch-loss value is not just financial — it is clinical.

This context is also the most process-complex: viral vector production, lentiviral transduction, T-cell expansion, and cryopreservation each have their own failure modes, their own state machines, and their own regulatory scrutiny. Praescia is designed to bring the same foreknowing to cell and gene therapy manufacturing that it brings to upstream bioprocess — with the additional sensitivity the stakes demand.

Cell & gene therapy specifics

• Viral vector titer and infectivity prediction pre-harvest
• T-cell expansion trajectory monitoring (viability, expansion fold, phenotype proxy signals)
• Cryopreservation process state monitoring
• Chain-of-identity and chain-of-custody tracking (patient-specific materials)
• Cold-chain excursion risk for patient-specific product shipments

Fill-finish and drug-product operations are constraint-driven: the line bottleneck, the environmental monitoring excursion, the changeover timing, the vial-inspection reject rate. These are the signals that, left undetected, become deviation reports, failed batches, and missed release dates.

Praescia’s fill-finish mode is built on Atlas PC — the production constraint spine — combined with Atlas OI for cleanroom and utility state monitoring. The result is a live picture of the line’s operational state and the trajectory of each constraint before it becomes a batch-record event.

Fill-finish detection targets

• Bottleneck transition onset (which station, what severity, projected throughput loss)
• Environmental monitoring excursion onset (particle counts, bioburden, temperature)
• WFI and purified water system state drift
• HVAC and differential pressure monitoring
• Vial-reject rate trend detection (inspection machine degradation, stopper/vial quality)
• Changeover state tracking (cleanroom status, equipment certification)

Bioreactor, PAT instrument, and in-line sensor vendors have the closest relationship with the batch data — and the deepest opportunity to differentiate on intelligence above the raw signal. Praescia’s OEM path licenses the Biopharma State Spine to run embedded in a vendor’s hardware or software stack, with the “Atlas Inside” mark.

For the vendor, this means: the intelligence is differentiated, validated, and arrives with the GxP compliance shell already in place. For the customer, it means the foreknowing is embedded in the instrument they already trust.

OEM terms

• License the Biopharma State Spine per-unit or per-seat
• GxP compliance shell included in the license
• Co-branding: “Powered by Praescia · Atlas Inside”
• Joint validation support package for OEM deployments
• Network-layer participation optional (opt-in per deployment)

Contact us for OEM partnership terms.